168 related articles for article (PubMed ID: 38455469)
1. Tumour cell-expressed PD-L1 reprograms lipid metabolism via EGFR/ITGB4/SREBP1c signalling in liver cancer.
Zhao M; Yuan H; Yang G; Wang Y; Bu Y; Zhang H; Zhao L; Lv P; Yun H; Geng Y; Feng J; Hou C; Wang S; Zhang N; Lu W; Zhang X
JHEP Rep; 2024 Apr; 6(4):101009. PubMed ID: 38455469
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma.
Kan A; Liu S; He M; Wen D; Deng H; Huang L; Lai Z; Huang Y; Shi M
JHEP Rep; 2024 Jan; 6(1):100939. PubMed ID: 38074509
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway.
Wang S; Li J; Xie J; Liu F; Duan Y; Wu Y; Huang S; He X; Wang Z; Wu X
Oncogene; 2018 Jul; 37(30):4164-4180. PubMed ID: 29706653
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
6. Shenqi Fuzheng injection modulates tumor fatty acid metabolism to downregulate MDSCs infiltration, enhancing PD-L1 antibody inhibition of intracranial growth in Melanoma.
Ma Y; Qi Y; Zhou Z; Yan Y; Chang J; Zhu X; Han J; Wu H; Tao Y; Fan F
Phytomedicine; 2024 Jan; 122():155171. PubMed ID: 37925891
[TBL] [Abstract][Full Text] [Related]
7. Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy.
Yan C; Wu D; Gan L; Wang J; Yang W; Xu B
Front Pharmacol; 2022; 13():949745. PubMed ID: 36034789
[No Abstract] [Full Text] [Related]
8. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
Ma SR; Liu JF; Jia R; Deng WW; Jia J
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
[TBL] [Abstract][Full Text] [Related]
9. An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway.
Leng C; Zhang ZG; Chen WX; Luo HP; Song J; Dong W; Zhu XR; Chen XP; Liang HF; Zhang BX
Cancer Lett; 2016 Jun; 376(1):188-96. PubMed ID: 26996299
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
12. Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis.
Ruan S; Lin M; Zhu Y; Lum L; Thakur A; Jin R; Shao W; Zhang Y; Hu Y; Huang S; Hurt EM; Chang AE; Wicha MS; Li Q
Cancer Res; 2020 Feb; 80(4):771-783. PubMed ID: 31843981
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
14. Chronic nicotine exposure affects programmed death-ligand 1 expression and sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
Yeo CD; Kim IK; Ban WH; Kang HS; Kim JW; Kim SJ; Park JY; Lee SH
Transl Cancer Res; 2019 Jul; 8(Suppl 4):S378-S388. PubMed ID: 35117115
[TBL] [Abstract][Full Text] [Related]
15. lncRNA EGFR-AS1 facilitates leiomyosarcoma progression and immune escape via the EGFR-MYC-PD-L1 axis.
Chen ML; Fan L; Huang GR; Sun ZF
Int Immunol; 2022 Jul; 34(7):365-377. PubMed ID: 35485964
[TBL] [Abstract][Full Text] [Related]
16. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
17. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract][Full Text] [Related]
18. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
[TBL] [Abstract][Full Text] [Related]
19. Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells.
Chen M; Sharma A; Lin Y; Wu Y; He Q; Gu Y; Xu ZP; Monteiro M; Gu W
BMC Cancer; 2019 Feb; 19(1):153. PubMed ID: 30770752
[TBL] [Abstract][Full Text] [Related]
20. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
